Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin in Relapsing-Remitting Multiple Sclerosis
NCT01279876Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Oct 2010
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing Melatonin with Placebo (2 arms). Primary endpoints: Number of relapses at 1 year, Expanded Disability Status Scale at 1 year and 2 more. Started Oct 2010; status: completed.
02
Drugs
melatonin
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01279876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01279876.